ClinicalTrials.gg
RecruitingNCT07018726Updated Oct 6, 2026

Addressing Emotional Distress in Dyads of Persons With a Young Onset Dementia (YOD) and Their Care-partners

An interventional study of Resilient Together-YOD and Health Enhancement Program-YOD in Young Onset Dementia, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.
Updated Oct 6, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
388
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Dementia by Massachusetts General Hospital — 6 open to participants now, 7 under way, none of them phase 3. Dementia · Massachusetts General Hospital.

Planned enrollment
Largest of 15
388 · median 30
Started
2026
with 2 others
No phase
13 of 18
4 open now
Registered
17th of 18
by date

Among the 18 studies in Dementia by Massachusetts General Hospital, this one has the largest planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2026, is one of 13 with no phase, and was the 17th registered.

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

6 of the 18 studies in Dementia by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Dementia by Massachusetts General Hospital, or all of them as a file.
02

Study summary

The purpose of the present investigation is to test the efficacy of a virtual, brief (6 sessions) dyadic (patient and care-partner together) intervention to prevent chronic emotional distress in dyads where one person is diagnosed with Young Onset Dementia (YOD). Through this study, we seek to address the unmet need of preventing chronic emotional distress in YOD dyads through a feasible, acceptable and credible program, and ideally enhance resiliency and improve wellbeing and quality of life in both members of the dyad.

03

Conditions studied

  • Young Onset Dementia

Browse trials for

Keywords

  • Emotional Distress
  • Dyadic Intervention
  • Young Onset Dementia
  • Caregiving
04

Who can participate

The criteria were revised on the registry on Oct 6, 2026. See what changed

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patient Criteria:

  • 40 years of age or older
  • Diagnosis of young-onset dementia (FTD, PPA, AD, PCA, etc.) with symptom onset prior to age 65 or evidence of familial AD onset up to age 70
  • Received YOD diagnosis in the past 10 months
  • English fluency and literacy
  • Cognitive ability to understand study and research protocol in order to consent to participation in intervention per referring neurologist and/or consent teach back questions
  • Must have a care-partner willing to participate

Care-Partner Criteria:

  • 18 years of age or older
  • Care-partner to person diagnosed with young-onset dementia (FTD, PPA, AD, PCA, etc.)
  • English fluency and literacy

Dyad Criteria: (Both Patient and Care-Partner):

-At least one dyad member reports elevated emotional distress (HADS>7)

Exclusion criteria

Exclusion Criteria:

  • An additional, terminal diagnosis such as cancer
  • Unwillingness to participate and use zoom for video conferencing
  • Current untreated or unstable severe mental health conditions like bipolar disorder, schizophrenia, or active substance use
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
388 participants (estimated)

Study arms

  • Experimental
    Experimental: Experimental Patient-Caregiver Dyads

    There will be 6 sessions delivered via live video using Zoom. Content will be primarily skills.

    Behavioral: Resilient Together-YOD

  • Active comparator
    Control Patient-Caregiver Dyads

    There will be 6 sessions delivered via live video using Zoom. Content will be primarily educational.

    Behavioral: Health Enhancement Program-YOD

Interventions

  • BehavioralResilient Together-YOD

    This is a 6 session dyadic (patient and spousal care-partner) intervention that teaches resiliency and interpersonal communication skills early after YOD diagnoses. It aims to decrease heightened symptoms of depression and anxiety among dyads to help them engage in important decisions around long term care-planning and optimize adjustment. The goal is to equip dyads with the necessary skills to cope and engage in meaningful, challenging conversations around care-planning, symptom deterioration, work/family planning to improve well-being in both members of the dyad.

    Also known as: Skills-based intervention

  • BehavioralHealth Enhancement Program-YOD

    This is a 6 session program that will deliver educational information to dyads and will mimic the dose and duration of Resilient Together. The program will not teach any individual and dyadic interpersonal skills, but will contain education on psychological distress and healthy behaviors. Sessions will also be delivered virtually.

    Also known as: Educational program

06

What researchers measure

Primary outcomes

  1. Change in Emotional Distress

    Hospital Depression and Anxiety Scale total score (HADS); 0-21 for each subscale (anxiety and depression), higher scores indicate greater anxiety or depression

    Time frame: 0 weeks, 6 weeks, 12 weeks

Secondary outcomes

  1. Change in Resiliency Factors (Mindfulness)

    Cognitive and Affective Mindfulness Scale (CAMS); 12-48, higher scores indicate greater perceived mindfulness

    Time frame: 0 weeks, 6 weeks, 12 weeks

  2. Change in Resiliency Factors (Individual Coping)

    Measure of Current Status Part A (MOCS-A) Assertiveness and Coping Confidence subscales; Subscale scores: 0-4; higher scores indicate greater perceived ability to cope

    Time frame: 0 week, 6 weeks, 12 weeks

  3. Change in Resiliency Factors (Mindfulness Utilization)

    Applied Mindfulness Scale (AMPS); 0-60, higher scores indicate greater use of mindfulness practices.

    Time frame: 0 weeks, 6 weeks, 12 weeks

  4. Changes in Interpersonal Factors (Dyad Coping)

    Dyadic Coping Inventory (DCI); 37-185, higher scores indicate greater perceived coping in the context of a relationship

    Time frame: 0 weeks, 6 weeks, 12 weeks

  5. Changes in Resiliency Factors (Perceived Social Support)

    Multidimensional Scale of Perceived Social Support (MSPSS); 12-84, higher scores indicate greater perceived social support from family, friends, and significant others

    Time frame: 0 weeks, 6 weeks, 12 weeks

  6. Changes in Resiliency Factors (Values-based Living)

    Valuing Questionnaire (VQ); Progress and Obstruction Subscale Scores: 0-30, higher scores indicate living in greater accordance with one's values

    Time frame: 0 weeks, 6 weeks, 12 weeks

Other outcomes

  1. Global Impressions of Change

    Modified Global Impressions of Chance (MGIC); 1-7, higher scores indicate greater perceived change in outcomes

    Time frame: 6 weeks, 12 weeks

  2. Cognition

    Montreal Cognitive Assessment (MoCA); 0-30, lower scores indicate greater cognitive dysfunction

    Time frame: 0 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jul 2030, 53 months after the start.

Of 862 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 53 months is above that.

Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2025
First posted
Jun 12, 2025
StartActual
Jan 28, 2026
Primary completionEst.
Jul 1, 2030
CompletionEst.
Jan 1, 2031
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
Maximum age 65 Years→70 Years; 6 inclusion criteria edited, 7 added, 1 removed; 1 exclusion criterion added, 1 removed
What changed in the criteria
Inclusion criteria
  • RemovedBetween the ages of 18-65 at the time of enrollment [both patient and care-partner]
  • AddedPatient Criteria:
  • Added40 years of age or older
  • EditedDiagnosis of young-onset dementia (FTD, PPA, AD, PCA, etc.) with symptom onset prior to age 65 [patient]or evidence of familial AD onset up to age 70
  • EditedReceived YOD diagnosis in the past 6 month [patient]10 months
  • AddedEnglish fluency and literacy
  • EditedCognitive ability to understand study and research protocol in order to consent to study participationparticipation in intervention per referring neurologist [both patient and care-partner]and/or consent teach back questions
  • EditedA designatedMust have a care-partner willing and interested to participate [both patient and care-partner]
  • AddedCare-Partner Criteria:
  • Added18 years of age or older
  • AddedCare-partner to person diagnosed with young-onset dementia (FTD, PPA, AD, PCA, etc.)
  • AddedEnglish fluency and literacy
  • EditedEnglish fluencyDyad Criteria: (Both Patient and literacy [both patient and careCare-partner]Partner):
  • ChangedBefore Patient and/or caregiver exhibit emotional distress on screening (using HADS D and/or HADS A scores > 7)Now -At least one dyad member reports elevated emotional distress (HADS>7)
Exclusion criteria
  • RemovedLack of access to internet and/or a device with a camera
  • AddedUnwillingness to participate and use zoom for video conferencing
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Eligibility Maximum age 65 Years→70 Years; 6 inclusion criteria edited, 7 added, 1 removed; 1 exclusion criterion added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedBetween the ages of 18-65 at the time of enrollment [both patient and care-partner]
    • AddedPatient Criteria:
    • Added40 years of age or older
    • EditedDiagnosis of young-onset dementia (FTD, PPA, AD, PCA, etc.) with symptom onset prior to age 65 [patient]or evidence of familial AD onset up to age 70
    • EditedReceived YOD diagnosis in the past 6 month [patient]10 months
    • AddedEnglish fluency and literacy
    • EditedCognitive ability to understand study and research protocol in order to consent to study participationparticipation in intervention per referring neurologist [both patient and care-partner]and/or consent teach back questions
    • EditedA designatedMust have a care-partner willing and interested to participate [both patient and care-partner]
    • AddedCare-Partner Criteria:
    • Added18 years of age or older
    • AddedCare-partner to person diagnosed with young-onset dementia (FTD, PPA, AD, PCA, etc.)
    • AddedEnglish fluency and literacy
    • EditedEnglish fluencyDyad Criteria: (Both Patient and literacy [both patient and careCare-partner]Partner):
    • ChangedBefore Patient and/or caregiver exhibit emotional distress on screening (using HADS D and/or HADS A scores > 7)Now -At least one dyad member reports elevated emotional distress (HADS>7)
    Exclusion criteria
    • RemovedLack of access to internet and/or a device with a camera
    • AddedUnwillingness to participate and use zoom for video conferencing

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07018726
Responsible party
Ana-Maria Vranceanu, PhD (Full Professor/Director, Massachusetts General Hospital) — Principal investigator
First posted
Jun 12, 2025
Start date
Jan 28, 2026
Primary completion
Jul 1, 2030 (estimated)
Completion
Jan 1, 2031 (estimated)
Last update
Oct 6, 2026

Study contacts

Ana-Maria Vranceanu, PhD
Contact
avranceanu@mgh.harvard.edu
617-724-4977
Maggie L Syme, PhD, MPH
Contact
msyme@mgh.harvard.edu

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion